Panelists:
Susan Abu-Absi, PhD
Cell and Gene Therapy
CMC Expert
Stephen Sofen, PhD
Chief Technology Officer
Abata Therapeutics
Julianna LeMieux, PhD
Deputy Editor-in-Chief
GEN
(Moderator)
- Time:
Bioprocessing is not only the lifeblood of drug development but also the field where GEN got its start—45 years ago! That said, the processes, equipment, and technology underlying drug manufacturing are evolving quickly, placing a premium on efficiency and safety as organizations advance novel therapies and modalities.
On this episode of GEN Live, we will discuss where bioprocessing is now and how the field plans to overcome its big challenges, with a pair of industry experts: Dr. Susan Abu-Absi and Dr. Stephen Sofen. Among the topics we will discuss: What are the major trends in cell and gene therapy (CGT), automation, quality control? How are cell therapy companies scaling up manufacturing to bring down the cost of goods? How is the role of CDMOs evolving? What impact will AI have in transforming CGT manufacturing?
We will also discuss highlights from the recent Bioprocessing Summit and preview the upcoming Bioprocessing International meeting (September 23–26 in Boston).
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post What’s Tipping the Scale for Bioprocessing? appeared first on GEN – Genetic Engineering and Biotechnology News.
